SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-22-046850
Filing Date
2022-04-18
Accepted
2022-04-18 16:02:15
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A tm223661d2_defa14a.htm DEFA14A 16712
2 GRAPHIC tm223661d2_defa14a-img001.jpg GRAPHIC 246034
3 GRAPHIC tm223661d2_defa14a-img002.jpg GRAPHIC 247100
  Complete submission text file 0001104659-22-046850.txt   697265
Mailing Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421
Business Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421 617-513-8774
Keros Therapeutics, Inc. (Filer) CIK: 0001664710 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39264 | Film No.: 22832159
SIC: 2834 Pharmaceutical Preparations